News & Updates
Filter by Specialty:
Mid-dose beta-blocker therapy tied to highest mortality reduction after AMI
Use of any beta-blocker dose results in a significant decrease in mortality following acute myocardial infarction (AMI) when compared with no treatment, reports a study. Doses >25 percent to 50 percent of the currently recommended target dose (RTD) are associated with highest mortality reduction within the first year after AMI, indicating that higher doses are not required.
Mid-dose beta-blocker therapy tied to highest mortality reduction after AMI
09 May 2023
Bisphosphonate, denosumab not linked to acute cardiovascular risk
Use of oral bisphosphonate or denosumab does not appear to increase the risk of cardiovascular events (CVEs), namely acute myocardial infarction, unstable angina, cerebrovascular accident, and transient ischemic attack, in persons with incident fracture, a study has shown.
Bisphosphonate, denosumab not linked to acute cardiovascular risk
06 May 2023
Preconception HBV history linked to congenital heart disease risk in offspring
Children born to mothers who had contracted hepatitis B virus (HBV) infection before pregnancy appear to be at increased risk of congenital heart diseases (CHDs), as reported in a study.
Preconception HBV history linked to congenital heart disease risk in offspring
04 May 2023
Is hypotension avoidance better than hypertension avoidance in noncardiac surgery?
The incidence of major vascular complications among patients who underwent noncardiac surgery is similar between hypotension- and hypertension-avoidance strategies, reports a study.
Is hypotension avoidance better than hypertension avoidance in noncardiac surgery?
04 May 2023
Poor awareness of hypertension self-management practices persists: study
A recent study conducted in Nigeria from December 2019 to February 2020 has revealed many individuals with little to no awareness of hypertension self-management practices.